Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures

This study has been terminated.
(No suitable case available and many techinical error)
Sponsor:
Information provided by (Responsible Party):
Rapat Pittayanon, MD, King Chulalongkorn Memorial Hospital
ClinicalTrials.gov Identifier:
NCT01501474
First received: December 27, 2011
Last updated: July 1, 2014
Last verified: July 2014
  Purpose

Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures

Objectives

  1. To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
  2. To assess the sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis

Study design One academic center, prospective, diagnostic study

Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital


Condition
Malignant Biliary Strictures

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures

Further study details as provided by King Chulalongkorn Memorial Hospital:

Primary Outcome Measures:
  • Increasing the detection rate of malignant biliary stricture diagnosis by using CholangioFlex (Cofocal) and/or FISH test [ Time Frame: up to 1 year ] [ Designated as safety issue: Yes ]
    If investigator can detect malignant biliary stricture more than present, the care giver can treat these patients properly. Consequently, the mortality rate of malignant biliary stricture will be decrease.


Biospecimen Retention:   Samples Without DNA

Brush cytology and FISH test


Enrollment: 5
Study Start Date: January 2012
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
CholangioFlex and Fluorescent in situ Hybridization(FISH)

  Hide Detailed Description

Detailed Description:

Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures

Objectives

  1. To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
  2. To assess the sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis

Study design One academic center, prospective, diagnostic study

Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital

Inclusion Criteria

  1. Age > 20 year-old
  2. All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
  3. All patients have to sign the consent form Exclusion Criteria

1.Cannot follow up for 1 year 2.Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants 3.Pregnancy 4.History of fluorescein allergy

Timeline: From January 2012 to December 2013

Sample size Due to no study in Thai population before, investigator will perform pilot study in 50 malignant biliary stricture patients

Method

  1. All patients had informed the consent.
  2. Take the history, physical examination and then fill in the record form 3.5 ml of blood sampling for CA19-9 and 20 ml for further test by keeping in -20c temperature for 5 years

4.Set confocal endomicroscopy at the same session of ERCP 5.After successfully cannulation;

  • 10% Fluorescein sodium 2.5 ml was injected intravenously.
  • Confocal endomicroscopy (CholangioFlex) was performed at the suspected area. The video will record the images with Cellvizio program recorder.

    6.Brush cytology was performed 7.Record the duration and complication of the procedure 8.Send the tissues to one clinically-blinded GI pathologist for pathological diagnosis and FISH test 9.Compare the pathology and FISH report and endoscopic finding 10.Report the result According to Miami-criteria 2009, the Criteria for malignant biliary stricture from CholangioFlex are one of the followings;

    1. Thick branching bands (>20 microns)
    2. Dark clumps or glands (usually measuring > 60 microns)
    3. Bright and tortuous vessels

      Follow up

  • The patients who are diagnosed malignant biliary obstruction will be treated as standard management
  • The patients who are not diagnosed malignant biliary obstruction will be followed up every 3 months for 1 year
  • The gold standard is pathology or clinical of malignancy including evidence of metastasis.

Statistical analysis Sensitivity, specificity, negative predictive value(NPV), positive predictive value(PPV) and accuracy by McNemar's test

Ethical considerations There is not a clearly evidence about the significant serious side effect of fluorescein injection. If the patients have side effects during the research, the procedure will be terminated and the patients will be in the responsibility of all investigators.

Expected benefit and application

  1. Increase rate of malignant biliary stricture diagnosis by using CholangioFlex and/or FISH test
  2. Decrease the mortality rate of malignant biliary stricture
  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Due to no study in Thai population before, investigator will perform pilot study in 50 malignant biliary stricture patients

Criteria

Inclusion Criteria:

  1. Age > 20 year-old
  2. All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
  3. All patients have to sign the consent form

Exclusion Criteria:

  1. Cannot follow up for 1 year
  2. Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants
  3. Pregnancy
  4. History of fluorescein allergy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01501474

Locations
Thailand
Rapat Pittayanon
Bangkok, Thailand, 10330
Sponsors and Collaborators
King Chulalongkorn Memorial Hospital
Investigators
Principal Investigator: Rapat Pittayanon, MD Chulalongkorn Hospital
Study Director: Rungsun Rerknimitr, Professor Chulalongkorn Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: Rapat Pittayanon, MD, King Chulalongkorn Memorial Hospital
ClinicalTrials.gov Identifier: NCT01501474     History of Changes
Other Study ID Numbers: RP004
Study First Received: December 27, 2011
Last Updated: July 1, 2014
Health Authority: Thailand: Ethical Committee

Keywords provided by King Chulalongkorn Memorial Hospital:
Confocal
malignant biliary stricture
Sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis

Additional relevant MeSH terms:
Cholestasis
Constriction, Pathologic
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on August 26, 2014